Product Description
Yuhan was developing yhd-1023, an oral PDE5 Inhibitor for Erectile Dysfunction
Mechanisms of Action: PDE5 Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Yuhan
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Erectile Dysfunction
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT01423370 |
YHD1023-201 | P2 |
Completed |
Erectile Dysfunction |
2013-03-01 |
2019-03-19 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|